The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Global (CGB) shares jump after its cannabis hard pills were received in Australia
  • Cann began importing the cannabis pills in late March following the green light by Health Canada
  • Currently, two of its six products have been shipped, with the remaining four arriving soon
  • The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs
  • On market close, Cann is up 20 per cent and trading at 0.6 cents per share

Cann Global (CGB) shares jumped today after its cannabis hard pills were received in Australia.

The company launched its products last October with its Canadian joint venture partner Canntab Therapeutics.

Cann began importing the cannabis pills in late March after receiving the green light by Health Canada.

Currently, two of its six products have been shipped, with the remaining four arriving soon.

According to Cann, its products are unique because of the patented hard pill form in which they come in, allowing for more precise dosing.

The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs.

“The products can be prescribed by practitioners via the Special Access Scheme Category B application pathway,” the company told the market.

Cann Global will update the market when the remaining four products have arrived in Australia.

On market close, Cann is up 20 per cent and trading at 0.6 cents per share.


CGB by the numbers
More From The Market Online
Closeup of IV fluid

Tryptamine psilocin treatment ruled safe in IV infusion during early trial

Tryptamine Therapeutics Ltd has been told by a Safety Committee that its IV-infused psilocin therapy is…
Australian currency

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

InhaleRX is set to go ahead with clinical trials after Victorian VC firm Clendon handed IRX…
Image of hands holding money

Telix Pharmaceuticals’ quarterly revenue exceeds AU$200M

Telix Pharmaceuticals (ASX:TLX) reveals its quarterly revenues while also reaffirming its full-year 2024 revenue guidance.
Medical project manager using a laptop

Pro Medicus snaffles 5-year contract extension worth $32M for RIS technology

Healthcare informatics company Pro Medicus Ltd (ASX:PME) has signed a 5-year contract extension – valued at a minimum of $32 million –